Find information on thousands of medical conditions and prescription drugs.

Antiphospholipid syndrome

Antiphospholipid syndrome (or antiphospholipid antibody syndrome) is a disorder of coagulation which causes thrombosis in both arteries and veins, as well as recurrent miscarriage. It is due to the autoimmune production of antibodies against cell membrane constituents. It is occasionally referred to as Hughes' syndrome after the rheumatologist Dr Graham R.V. Hughes (St. Thomas' Hospital, London, UK). more...

Home
Diseases
A
Aagenaes syndrome
Aarskog Ose Pande syndrome
Aarskog syndrome
Aase Smith syndrome
Aase syndrome
ABCD syndrome
Abdallat Davis Farrage...
Abdominal aortic aneurysm
Abdominal cystic...
Abdominal defects
Ablutophobia
Absence of Gluteal muscle
Acalvaria
Acanthocheilonemiasis
Acanthocytosis
Acarophobia
Acatalasemia
Accessory pancreas
Achalasia
Achard syndrome
Achard-Thiers syndrome
Acheiropodia
Achondrogenesis
Achondrogenesis type 1A
Achondrogenesis type 1B
Achondroplasia
Achondroplastic dwarfism
Achromatopsia
Acid maltase deficiency
Ackerman syndrome
Acne
Acne rosacea
Acoustic neuroma
Acquired ichthyosis
Acquired syphilis
Acrofacial dysostosis,...
Acromegaly
Acrophobia
Acrospiroma
Actinomycosis
Activated protein C...
Acute febrile...
Acute intermittent porphyria
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute mountain sickness
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute necrotizing...
Acute promyelocytic leukemia
Acute renal failure
Acute respiratory...
Acute tubular necrosis
Adams Nance syndrome
Adams-Oliver syndrome
Addison's disease
Adducted thumb syndrome...
Adenoid cystic carcinoma
Adenoma
Adenomyosis
Adenosine deaminase...
Adenosine monophosphate...
Adie syndrome
Adrenal incidentaloma
Adrenal insufficiency
Adrenocortical carcinoma
Adrenogenital syndrome
Adrenoleukodystrophy
Aerophobia
Agoraphobia
Agrizoophobia
Agyrophobia
Aicardi syndrome
Aichmophobia
AIDS
AIDS Dementia Complex
Ainhum
Albinism
Albright's hereditary...
Albuminurophobia
Alcaptonuria
Alcohol fetopathy
Alcoholic hepatitis
Alcoholic liver cirrhosis
Alektorophobia
Alexander disease
Alien hand syndrome
Alkaptonuria
Alliumphobia
Alopecia
Alopecia areata
Alopecia totalis
Alopecia universalis
Alpers disease
Alpha 1-antitrypsin...
Alpha-mannosidosis
Alport syndrome
Alternating hemiplegia
Alzheimer's disease
Amaurosis
Amblyopia
Ambras syndrome
Amelogenesis imperfecta
Amenorrhea
American trypanosomiasis
Amoebiasis
Amyloidosis
Amyotrophic lateral...
Anaphylaxis
Androgen insensitivity...
Anemia
Anemia, Diamond-Blackfan
Anemia, Pernicious
Anemia, Sideroblastic
Anemophobia
Anencephaly
Aneurysm
Aneurysm
Aneurysm of sinus of...
Angelman syndrome
Anguillulosis
Aniridia
Anisakiasis
Ankylosing spondylitis
Ankylostomiasis
Annular pancreas
Anorchidism
Anorexia nervosa
Anosmia
Anotia
Anthophobia
Anthrax disease
Antiphospholipid syndrome
Antisocial personality...
Antithrombin deficiency,...
Anton's syndrome
Aortic aneurysm
Aortic coarctation
Aortic dissection
Aortic valve stenosis
Apert syndrome
Aphthous stomatitis
Apiphobia
Aplastic anemia
Appendicitis
Apraxia
Arachnoiditis
Argininosuccinate...
Argininosuccinic aciduria
Argyria
Arnold-Chiari malformation
Arrhythmogenic right...
Arteriovenous malformation
Arteritis
Arthritis
Arthritis, Juvenile
Arthrogryposis
Arthrogryposis multiplex...
Asbestosis
Ascariasis
Aseptic meningitis
Asherman's syndrome
Aspartylglycosaminuria
Aspergillosis
Asphyxia neonatorum
Asthenia
Asthenia
Asthenophobia
Asthma
Astrocytoma
Ataxia telangiectasia
Atelectasis
Atelosteogenesis, type II
Atherosclerosis
Athetosis
Atopic Dermatitis
Atrial septal defect
Atrioventricular septal...
Atrophy
Attention Deficit...
Autoimmune hepatitis
Autoimmune...
Automysophobia
Autonomic dysfunction
Familial Alzheimer disease
Senescence
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

A very rare form is the catastrophic antiphospholipid syndrome, in which there is rapid organ dysfunction and arterial hypertension. It carries a high mortality.

Signs and symptoms

The presence of antiphospholipid antibodies (APLAs) is suggested by thrombosis (arterial or venous) and recurrent miscarriage (especially in the second trimester, but often earlier). Other common findings, although not part of the classification, are thrombocytopenia (low platelet count) and livedo reticularis (a skin condition). Many patients report headaches.

APLAs are present in the blood in the context of a number of diseases, most notably systemic lupus erythematosus (SLE). One can only speak of antiphospolipid syndrome when there are no other symptoms of one of these diseases (e.g. arthritis suggestive of SLE). A number of patients with the syndrome (about 10%) will eventually develop SLE, but most never get signs of this disease.

Laboratory

The diagnosis is often entertained in cases of thrombophilia (recurrent thrombosis) or recurrent miscarriage. Tests that are often performed at the same time are a full blood count, liver enzyme studies and renal function studies.

Thrombophilia screening can consist of:

  • Screening coagulation studies: APTT, PT and TT.
  • Further studies for Factor V Leiden variant and the prothrombin mutation, Factor VIII levels, MTHFR mutation.
  • Levels of protein C, free and total protein S, Factor VIII, antithrombin, plasminogen, tissue plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1)

Antiphospholipid syndrome is tested for in the laboratory by using a minimum of two coagulation tests that are phospholipid sensitive. The patient on initial screening will typically have been found to have a prolonged APTT that does not correct in a 80:20 mixture with normal human plasma (50:50 mixes with normal plasma are insensitive to all but the highest antibody levels). The APTT (plus 80:20 mix), dilute Russell viper venom time (DRVVT), the kaolin clotting time (KCT) or dilute thromboplastin time {TDT/DTT) are the prinicipal tests used for the detection of lupus anticoagulant. A further antibody can be detected using an enzyme-linked immunosorbant assay (ELISA) immunological test, which screens for the presence of antibodies to anticardiolipin.

Low platelet count and positivity for antibodies against β2-glycoprotein or phosphotidylserine may also be observed in a positive diagnosis.

Diagnosis

The diagnosis is made in case of a clinical event (thrombosis or recurrent miscarriage after 10 weeks gestation) and repeated positive tests of lupus anticoagulant and/or anticardiolipin antibodies performed 6-8 weeks apart. Repeat testing is necessary due to the naturally occurring presence of transient high levels of antiphospholipid antibodies following infection and inflammation. Other antibodies, although implicated, are not yet considered relevant for diagnosis.

Read more at Wikipedia.org


[List your site here Free!]


The antiphospholipid antibody syndrome: a vascular disease with pulmonary manifestations - Editorial
From CHEST, 12/1/97 by Jeffrey Pilling

It is rare that a new disease with respiratory manifestations arrives on the scene. The antiphospholipid antibody syndrome (APS) is a perplexing new entity that is approximately a decade old. APS is a hypercoagulable state characterized by the presence of autoantibodies to membrane phospholipids. Its major clinical features are vascular occlusion (eg, stroke, myocardial infarction, peripheral gangrene, visceral infarct, deep vein thrombosis), fetal loss, and hematologic abnormalities that mimic vasculitis (eg, thrombocytopenia, Coombs's positive hemolytic anemia, livedo reticularis).[1,2] Circulating immunoglobulins, anticardiolipin antibody (aCL), and a lupus anticoagulant (LAC) directed against membrane phospholipids play a central role in the pathogenesis of APS.[3,4]

APS is of interest to the pulmonologist because of its wide spectrum of respiratory manifestations. In this issue of CHEST (see page 1707) Kerr et al reported an atypical case of APS with ARDS features and no other systemic manifestations. The known manifestations of APS, such as recurrent pulmonary emboli with pulmonary hypertension, pulmonary hemorrhage, pulmonary arterial thrombosis, and ARDS, typically occur in the presence of systemic findings.[3,4,5] Another unique presentation is postpartum pulmonary artery thrombosis in association with pleural effusions, infiltrates, spiking fevers, and chest pain.[6]

APS is categorized as "primary" when it presents as an independent entity, or "secondary" when it appears with an underlying autoimmune disorder. The presentation is similar in both categories, but the distinction is important because of different prognostic and therapeutic concerns. For example, the coagulopathy of APS in association with systemic lupus erythematosus (SLE) is treated with anticoagulants, while inflammatory vasculitis secondary to SLE is treated with immunosuppressive drugs. Approximately 50% of APS cases present as primary disorders; the remainder occur in association with SLE, another connective tissue disorder, or less frequently ([is less than] 10%), idiopathic thrombocytopenic purpura.[7,8] The histopathologic marker of APS is a bland, noninflammatory thromboembolic occlusion of small or large vessels.[1,8] The vessels contain subendothelial deposits of material that appear positive with periodic acid-Schiff stain (PAS). Thus, APS is a vascular disease involving the endothelium as a primary target. The precise mechanism of the coagulopathy is not well defined, but does involve a complex interaction between antiphospholipid antibodies, clotting factors, and the vascular endothelium.[9,10]

The protean manifestations of APS make accurate diagnosis a challenge. The temporal relationship of the thromboembolic events and elevated antibody titers is poorly defined.[8,10] Since [is less than ] 10% of thromboembolic events are a result of hypercoagulable states, a high index of suspicion is required to identify cases of APS. In the setting of unexplained arterial or venous thrombosis or fetal loss, a first step is to determine the patient's ACL and LAC titers. In approximately 60% of APS cases, both titers are elevated. The other cases will have an elevation of only one test. Therefore, testing for both aCL and LAC is important. The IgG isotype most often correlates with that of thrombosis.[10] Antibody titers may be elevated persistently, or temporarily in response to infections, malignancy, and other acute conditions. One third of patients with SLE have antiphospholipid antibodies present, but many do not develop APS.[1,11] Approximately 2% of the general population have detectable antibodies, while 0.2% have high titers.[1,7] Low titers of antiphospholipid antibodies may be present in other autoimmune disorders, infectious diseases (HIV, syphilis, Lyme disease), malignancies, and drug reactions (to phenothiazine, procainamide, hydralazine, phenytoin), but may not be associated with thromboembolic events.[1,7]

Ideal therapeutic intervention for APS is as elusive as its diagnosis. Untreated thromboembolic events tend to be recurrent; the site of the first event often predicts the site of subsequent events. The median time for recurrence is 12 months.[8] There are no prospective randomized trials evaluating management strategies. Two retrospective analyses of 247 patients with APS concluded that high-dose warfarin (international normalized ratio [INR] [is greater than or equal to] 3.0) provided the best protection against recurrent events for patients with a confirmed history of thrombosis.[7,8] Anticoagulation with low or intermediate intensity warfarin, or heparin, provides limited protection from recurrence. Prophylactic use of aspirin alone provided no protective benefit. The results of these studies were inconclusive in determining whether concurrent use of aspirin and anticoagulants has any additional beneficial effect. While lifelong anticoagulation therapy carries a risk for bleeding, the consensus is that this risk is less than that of untreated APS.[1,7,8] Adverse side effects frequently accompany long-term use of steroids, cytotoxic agents, and plasmaphoresis. Therefore, caution is warranted in the use of treatments that have not been evaluated in a prospective clinical trial. It is not clear if patients with elevations of antiphospholipid titers but without clinical manifestations of APS benefit from aspirin or anticoagulant prophylaxis. Anticoagulation during pregnancy poses a special concern related to teratogenic problems with warfarin. Pregnant women with histories of recurrent spontaneous abortion may have better clinical outcomes using aspirin in combination with heparin or corticosteroid prophylaxis.[12-14]

There is limited information concerning optimal treatment of APS-associated pulmonary manifestations. A steroid-responsive form of ARDS may complicate either primary or secondary APS.[3,15] These patients appear to respond rapidly to IV steroids within hours or days.[3] The occurrence of ARDS is not surprising, since circulating immunoglobulins directed against membrane phospholipids can produce endothelial damage.[3,15] The basis for the response to steroids is unclear, and it runs counter to current recommendations for treating ARDS. A subset of APS patients with autoimmune capillaritis may benefit from combination treatment with steroids and immunosuppressive agents. Crausman et al[6] obtained rapid suppression of alveolar hemorrhage in several patients using methylprednisolone and cyclophosphamide followed by maintenance therapy.

In summary, APS is a noninflammatory pulmonary vasculopathy, including a chronic recurrent form not associated with an underlying disease. A major goal at this time is to clarify the pathogenesis of this complex disorder. In time, a prospective, randomized trial will guide us to the most effective therapeutic intervention. Do all APS cases represent one disease with a unified pathogenesis, or several related entities? Is this a primary disease of the endothelium, or of the clotting factors? What is the initiating factor for production of the auto-antibodies? These questions present a significant challenge; it remains to be seen what we can do for these patients.

References

[1] Lockshin MD. Answers to the antiphospholipid-antibody syndrome? N Engl J Med 1995; 332:1025-27

[2] Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Arthritis Rheum 1990; 20:81-96

[3] Ghosh S, Walters HD, Joist JH, et al. Adult respiratory distress syndrome associated with antiphospholipid antibody syndrome. J Rheumatol 1993; 20:1406-07

[4] Luchi ME, Asherson RA, Lahita RG. Primary idiopathic pulmonary hypertension complicated by pulmoany arterial thrombosis. Arthritis Rheum 1992; 35:700-05

[5] Crausman RS, Achenbach GA, Pluss WT, et al. Pulmonary capillaritis and alveolar hemorrhage associated with the antiphospholipid antibody syndrome. J Rheumatol 1995: 22: 554-56

[6] Branch DW, Kochenour NK, Rok NS, et al. A new postpartum syndrome associated with antiphospholipid antibodies. Obstetrics Gynecol 1987; 69:460-68

[7] Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303-08

[8] Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-97

[9] Asherson RA, Cervera R. Review: antiphospholipid antibodies and the lung. J Rheumatol 1995; 22:62-66

[10] Lockshin MD. Antiphospholipid antibody syndrome. Rheum Dis Clin North Am 1994; 20:45-59

[11] Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990; 112:682-98

[12] Branch DW, Scott JR, Kochenour NK, et al. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313:1322-26

[13] Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614-20

[14] Ordi J, Barquinero J, Vilardell M, et al. Fetal loss treatment in patients with antiphospholipid antibodies. And Rheum Dis 1989; 48:798-802

[15] Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19:508-12

COPYRIGHT 1997 American College of Chest Physicians
COPYRIGHT 2004 Gale Group

Return to Antiphospholipid syndrome
Home Contact Resources Exchange Links ebay